[New physiopathological roles for the PLA2R1 receptor in cancer and membranous nephropathy].

PLA2R1 is a large transmembrane receptor of 180-kDa that belongs to the superfamily of C-type lectins. It was discovered because of its high affinity for secreted phospholipases A2 (sPLA2), enzymes that play a key role in lipid mediator synthesis. Early PLA2R1 physiological roles include the clearance of sPLA2 from the extracellular medium and/or promotion of their actions. Over the last four years, two independent studies suggested that PLA2R1 plays a role in cancer as a tumor gene suppressor and is the major target antigen of auto-immune antibodies involved in idiopathic membranous nephropathy, a severe human kidney disease. These novel findings shed light on PLA2R1 and pave the way for its use as a reliable biomarker and an attractive therapeutic target in these diseases.

[1]  A. Tedgui,et al.  [Lp-PLA2 and sPLA2: cardiovascular biomarkers]. , 2014, Medecine sciences : M/S.

[2]  C. Ponticelli,et al.  Glomerular diseases: membranous nephropathy--a modern view. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[3]  D. Bernard,et al.  PLA2R1 kills cancer cells by inducing mitochondrial stress. , 2013, Free radical biology & medicine.

[4]  M. Gelb,et al.  PLA2R1 mediates tumor suppression by activating JAK2. , 2013, Cancer research.

[5]  J. Wetzels,et al.  Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[6]  L. McWilliam,et al.  Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. , 2013, Kidney international.

[7]  J. Campisi Aging, cellular senescence, and cancer. , 2013, Annual review of physiology.

[8]  G. Eisenhofer,et al.  Aberrant methylation of the M-type phospholipase A2 receptor gene in leukemic cells , 2012, BMC Cancer.

[9]  J. Wetzels,et al.  Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.

[10]  M. Stegall,et al.  The Pathology and Clinical Features of Early Recurrent Membranous Glomerulonephritis , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  H. Debiec,et al.  Pathogenesis of membranous nephropathy: recent advances and future challenges , 2012, Nature Reviews Nephrology.

[12]  E. Rondeau,et al.  Autoantibodies Specific for the Phospholipase A2 Receptor in Recurrent and De Novo Membranous Nephropathy , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  David M. Beck,et al.  Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[14]  David M. Beck,et al.  Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[15]  L. Kiemeney,et al.  Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. , 2011, The New England journal of medicine.

[16]  H. Debiec,et al.  PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. , 2011, The New England journal of medicine.

[17]  R. Stahl,et al.  PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. , 2010, The New England journal of medicine.

[18]  Kei Yamamoto,et al.  Emerging roles of secreted phospholipase A2 enzymes: Lessons from transgenic and knockout mice. , 2010, Biochimie.

[19]  D. Bernard,et al.  [Senescent-associated factors: pro- and anti-tumoral actions]. , 2009, Medecine sciences : M/S.

[20]  David M. Beck,et al.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. , 2009, The New England journal of medicine.

[21]  D. Bernard,et al.  The M‐type receptor PLA2R regulates senescence through the p53 pathway , 2009, EMBO reports.

[22]  Kwang Seok Kim,et al.  Induction of cellular senescence by secretory phospholipase A2 in human dermal fibroblasts through an ROS-mediated p53 pathway. , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.

[23]  A. Dejean,et al.  [A review of cellular senescence: friend or foe of tumorigenesis?]. , 2009, Medecine sciences : M/S.

[24]  M. Gelb,et al.  Biochemistry and physiology of mammalian secreted phospholipases A2. , 2008, Annual review of biochemistry.

[25]  James G. Bollinger,et al.  Importance of group X–secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model , 2007, The Journal of experimental medicine.

[26]  M. Gelb,et al.  Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor. , 2007, Biochemistry.

[27]  C. Isacke,et al.  The mannose receptor family. , 2002, Biochimica et biophysica acta.

[28]  H. Arita,et al.  Phospholipase A2 receptor: a regulator of biological functions of secretory phospholipase A2. , 2002, Prostaglandins & other lipid mediators.

[29]  J. Haymann,et al.  Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. , 2002, The New England journal of medicine.

[30]  H. Arita,et al.  Identification of a Soluble Form Phospholipase A2Receptor as a Circulating Endogenous Inhibitor for Secretory Phospholipase A2 * , 2002, The Journal of Biological Chemistry.

[31]  N. Fujii,et al.  Enhanced tissue expression and elevated circulating level of phospholipase A(2) receptor during murine endotoxic shock. , 2000, Archives of biochemistry and biophysics.

[32]  M. Lazdunski,et al.  Receptors for a growing family of secreted phospholipases A2. , 1999, Trends in pharmacological sciences.

[33]  M. Lazdunski,et al.  Both Group IB and Group IIA Secreted Phospholipases A2 Are Natural Ligands of the Mouse 180-kDa M-type Receptor* , 1999, The Journal of Biological Chemistry.

[34]  J. Fayard,et al.  Nuclear location of PLA2-I in proliferative cells. , 1998, Journal of cell science.

[35]  H. Arita,et al.  Resistance to Endotoxic Shock in Phospholipase A2 Receptor-deficient Mice* , 1997, The Journal of Biological Chemistry.

[36]  M. Lazdunski,et al.  Endocytic Properties of the M-type 180-kDa Receptor for Secretory Phospholipases A(*) , 1996, The Journal of Biological Chemistry.

[37]  M. Lazdunski,et al.  Identification of the Binding Domain for Secretory Phospholipases A2 on Their M-type 180-kDa Membrane Receptor * , 1995, The Journal of Biological Chemistry.

[38]  M. Lazdunski,et al.  Multifunctional activity of the extracellular domain of the M-type (180 kDa) membrane receptor for secretory phospholipases A2. , 1995, Biochemistry.

[39]  M. Lazdunski,et al.  The Human 180-kDa Receptor for Secretory Phospholipases A2 , 1995, The Journal of Biological Chemistry.

[40]  M. Lazdunski,et al.  Identification and purification of a very high affinity binding protein for toxic phospholipases A2 in skeletal muscle. , 1990, The Journal of biological chemistry.

[41]  D. Hackel,et al.  Production of Nephrotic Syndrome in Rats by Freund's Adjuvants and Rat Kidney Suspensions.∗ , 1959, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[42]  M. Murakami,et al.  This information is current as Inflammation Exacerbates Ovalbumin-Induced Lung Receptor 2 Deficiency of Phospholipase , 2013 .

[43]  M. Serrano,et al.  Senescence in tumours: evidence from mice and humans , 2010, Nature Reviews Cancer.

[44]  V. Guigonis,et al.  [Anti-CD10 fetomaternal alloimmunisation]. , 2009, Medecine sciences : M/S.